Research ExplorerPublicationsIs there a natural limit of the transformation rate of oral ...

Is there a natural limit of the transformation rate of oral leukoplakia?

Standard

Is there a natural limit of the transformation rate of oral leukoplakia? / Scheifele, Christian; Reichart, Peter A.

In: ORAL ONCOL, Vol. 39, No. 5, 01.07.2003, p. 470-5.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Scheifele, C & Reichart, PA 2003, 'Is there a natural limit of the transformation rate of oral leukoplakia?', ORAL ONCOL, vol. 39, no. 5, pp. 470-5. https://doi.org/10.1016/s1368-8375(03)00006-x

APA

Scheifele, C., & Reichart, P. A. (2003). Is there a natural limit of the transformation rate of oral leukoplakia? ORAL ONCOL, 39(5), 470-5. https://doi.org/10.1016/s1368-8375(03)00006-x

Vancouver

Scheifele C, Reichart PA. Is there a natural limit of the transformation rate of oral leukoplakia? ORAL ONCOL. 2003 Jul 1;39(5):470-5. https://doi.org/10.1016/s1368-8375(03)00006-x

Bibtex

@article{0fa0022dd7364c8d8e3db50639c0f6fe,
title = "Is there a natural limit of the transformation rate of oral leukoplakia?",
abstract = "Recent reviews described a cumulative risk of 0-38% of oral leukoplakias (OL) to transform into oral squamous cell carcinoma (OSCC). The annual transformation rate (ATR) of OL into OSCC amounted up to 6.3%. To elucidate epidemiological consequences of varying ATR. Variations of the prevalence (1-2%) and ATR (0.5-4%) of OL were used to compute the proportional incidences of OSCC developing in OL. These were compared to the actual incidences of OSCC excerpted from European cancer registries. A ratio <50% of predicted to actual incidence overall indicated a plausible ATR. With an ATR>or=3%, the predicted incidences of OSCC would exceed the reported incidences in all countries. With an ATR",
keywords = "Carcinoma, Squamous Cell/epidemiology, Data Collection/methods, Europe/epidemiology, Female, Humans, Incidence, Leukoplakia, Oral/epidemiology, Male",
author = "Christian Scheifele and Reichart, {Peter A}",
year = "2003",
month = jul,
day = "1",
doi = "10.1016/s1368-8375(03)00006-x",
language = "English",
volume = "39",
pages = "470--5",
journal = "ORAL ONCOL",
issn = "1368-8375",
publisher = "Elsevier Limited",
number = "5",

}

RIS

TY - JOUR

T1 - Is there a natural limit of the transformation rate of oral leukoplakia?

AU - Scheifele, Christian

AU - Reichart, Peter A

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Recent reviews described a cumulative risk of 0-38% of oral leukoplakias (OL) to transform into oral squamous cell carcinoma (OSCC). The annual transformation rate (ATR) of OL into OSCC amounted up to 6.3%. To elucidate epidemiological consequences of varying ATR. Variations of the prevalence (1-2%) and ATR (0.5-4%) of OL were used to compute the proportional incidences of OSCC developing in OL. These were compared to the actual incidences of OSCC excerpted from European cancer registries. A ratio <50% of predicted to actual incidence overall indicated a plausible ATR. With an ATR>or=3%, the predicted incidences of OSCC would exceed the reported incidences in all countries. With an ATR

AB - Recent reviews described a cumulative risk of 0-38% of oral leukoplakias (OL) to transform into oral squamous cell carcinoma (OSCC). The annual transformation rate (ATR) of OL into OSCC amounted up to 6.3%. To elucidate epidemiological consequences of varying ATR. Variations of the prevalence (1-2%) and ATR (0.5-4%) of OL were used to compute the proportional incidences of OSCC developing in OL. These were compared to the actual incidences of OSCC excerpted from European cancer registries. A ratio <50% of predicted to actual incidence overall indicated a plausible ATR. With an ATR>or=3%, the predicted incidences of OSCC would exceed the reported incidences in all countries. With an ATR

KW - Carcinoma, Squamous Cell/epidemiology

KW - Data Collection/methods

KW - Europe/epidemiology

KW - Female

KW - Humans

KW - Incidence

KW - Leukoplakia, Oral/epidemiology

KW - Male

U2 - 10.1016/s1368-8375(03)00006-x

DO - 10.1016/s1368-8375(03)00006-x

M3 - SCORING: Journal article

C2 - 12747971

VL - 39

SP - 470

EP - 475

JO - ORAL ONCOL

JF - ORAL ONCOL

SN - 1368-8375

IS - 5

ER -